MX387658B - Métodos para tratar y/o prevenir queratosis actínica. - Google Patents

Métodos para tratar y/o prevenir queratosis actínica.

Info

Publication number
MX387658B
MX387658B MX2019010707A MX2019010707A MX387658B MX 387658 B MX387658 B MX 387658B MX 2019010707 A MX2019010707 A MX 2019010707A MX 2019010707 A MX2019010707 A MX 2019010707A MX 387658 B MX387658 B MX 387658B
Authority
MX
Mexico
Prior art keywords
methods
actinic keratosis
treat
prevent actinic
prevent
Prior art date
Application number
MX2019010707A
Other languages
English (en)
Spanish (es)
Other versions
MX2019010707A (es
Inventor
David Lawrence Cutler
E Douglas Kramer
Jane Fang
Johnson Yiu - Nam Lau
Min- Fun Rudolf KWAN
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX387658(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Publication of MX2019010707A publication Critical patent/MX2019010707A/es
Publication of MX387658B publication Critical patent/MX387658B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019010707A 2017-03-10 2018-03-12 Métodos para tratar y/o prevenir queratosis actínica. MX387658B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (2)

Publication Number Publication Date
MX2019010707A MX2019010707A (es) 2020-01-15
MX387658B true MX387658B (es) 2025-03-18

Family

ID=63446658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010707A MX387658B (es) 2017-03-10 2018-03-12 Métodos para tratar y/o prevenir queratosis actínica.
MX2021013354A MX2021013354A (es) 2017-03-10 2019-09-09 Metodos para tratar y/o prevenir queratosis actinica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013354A MX2021013354A (es) 2017-03-10 2019-09-09 Metodos para tratar y/o prevenir queratosis actinica.

Country Status (13)

Country Link
US (3) US10617693B2 (enExample)
EP (2) EP3592355B1 (enExample)
JP (3) JP7502863B2 (enExample)
KR (2) KR20190141661A (enExample)
CN (1) CN110891575A (enExample)
AU (2) AU2018231144B2 (enExample)
BR (1) BR112019018687A2 (enExample)
CA (1) CA3055938A1 (enExample)
IL (1) IL269182B2 (enExample)
MX (2) MX387658B (enExample)
TW (1) TWI841523B (enExample)
WO (1) WO2018165647A1 (enExample)
ZA (1) ZA202100106B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica
FI3679016T3 (fi) 2017-09-07 2025-12-12 Atnx Spv Llc 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja
CA3092939C (en) * 2018-03-07 2024-10-08 Atnx Spv, Llc USE OF THE COMBINATION OF KX01 AND VITAMIN D TO TREAT HYPERPROLIFERATIVE SKIN DISORDERS
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
EP4263833A1 (en) * 2021-01-21 2023-10-25 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers
CN120152984A (zh) * 2023-10-13 2025-06-13 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
DK1836169T5 (da) 2004-12-28 2023-10-09 Atnx Spv Llc Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
RS58566B1 (sr) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corp Formulacije imikuimoda niže dozne jačine i kratkih režima doziranja za lečenje aktinične keratoze
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica

Also Published As

Publication number Publication date
KR20240090837A (ko) 2024-06-21
TWI841523B (zh) 2024-05-11
IL269182A (en) 2019-11-28
US10617693B2 (en) 2020-04-14
MX2019010707A (es) 2020-01-15
RU2019131757A3 (enExample) 2021-05-31
US11497750B2 (en) 2022-11-15
AU2024201828A1 (en) 2024-05-02
IL269182B1 (en) 2023-07-01
TW201842913A (zh) 2018-12-16
IL269182B2 (en) 2023-11-01
EP4659740A2 (en) 2025-12-10
KR20190141661A (ko) 2019-12-24
CN110891575A (zh) 2020-03-17
EP3592355B1 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
AU2018231144B2 (en) 2023-12-21
JP2023015269A (ja) 2023-01-31
BR112019018687A2 (pt) 2020-04-07
ZA202100106B (en) 2022-08-31
AU2018231144A1 (en) 2019-10-03
EP3592355A1 (en) 2020-01-15
US20230172942A1 (en) 2023-06-08
US20180256589A1 (en) 2018-09-13
CA3055938A1 (en) 2018-09-13
RU2019131757A (ru) 2021-04-12
JP2025029010A (ja) 2025-03-05
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
JP7502863B2 (ja) 2024-06-19
EP3592355A4 (en) 2021-01-06
JP2020510042A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
WO2017059319A3 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201790398A1 (ru) Способы лечения заболевания печени
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2018014938A (es) Combinaciones farmaceuticas para el tratamiento del cancer.
MX2017011018A (es) Inhibicion de la actividad de olig2.
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX2016014755A (es) Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
MX394015B (es) Inhibición de la actividad de la olig2.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp